BidaskClub Upgrades Sinovac Biotech (SVA) to Sell

BidaskClub upgraded shares of Sinovac Biotech (NASDAQ:SVA) from a strong sell rating to a sell rating in a research note published on Wednesday.

Separately, ValuEngine downgraded Sinovac Biotech from a buy rating to a hold rating in a research note on Tuesday, June 26th.

SVA opened at $7.55 on Wednesday. Sinovac Biotech has a 52 week low of $6.06 and a 52 week high of $8.75.



Several hedge funds have recently modified their holdings of SVA. Navellier & Associates Inc purchased a new position in shares of Sinovac Biotech during the 2nd quarter worth approximately $238,000. Yorktown Management & Research Co Inc purchased a new position in shares of Sinovac Biotech during the 2nd quarter worth approximately $482,000. Sapphire Star Partners LP purchased a new position in shares of Sinovac Biotech during the 2nd quarter worth approximately $723,000. Finally, California Public Employees Retirement System raised its stake in shares of Sinovac Biotech by 48.6% during the 1st quarter. California Public Employees Retirement System now owns 92,127 shares of the biopharmaceutical company’s stock worth $793,000 after buying an additional 30,127 shares in the last quarter. 11.32% of the stock is owned by institutional investors and hedge funds.

About Sinovac Biotech

Sinovac Biotech Ltd., a biopharmaceutical company, engages in the research, development, manufacture, and commercialization of vaccines against human infectious diseases in the People's Republic of China. The company's product portfolio includes vaccines against hepatitis A and B, enterovirus 71 (EV71), seasonal influenza, H5N1 and H1N1 pandemic influenza, and mumps, as well as hand, foot, and mouth diseases.

Further Reading: Understanding Market Liquidity

Receive News & Ratings for Sinovac Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sinovac Biotech and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply